Stephens analyst Chris Cooley raised his price target on DexCom shares to $170 from $160 following the company’s Q3 report and revenue guidance increase. He sees DexCom being well positioned to continued posting organic growth “in the top echelon of med tech” while realizing operating leverage. Cooley maintains an Overweight rating on DexCom shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.